Abstract This is a preliminary report on a case-series of rheumatoid patients that underwent various kinds of elective surgery but did not withdraw etanercept therapy in spite of physician advise. Elective surgery consisted of right knee surgical prosthesis, bilateral cataract, bilateral hallux valgus, right hip prosthesis, bladder stone by cystoscopy and left inguinal hernia. All the patients had a regular healing rate. During follow-up (6-12 months) no one of these patients were suffering from infective complications after surgery. According to same recent literature results, our data suggest that it is the time to value rheumatoid patient preferences through a correct information about cost-benefit of this treatment to establish together with patients if etanercept therapy has to be discontinued before and after elective surgery. Finally, we think that adverse drug reaction surveillance has to be boosted, and editors of leading scientific journal should publish more papers on case-series about drug safety and tolerability in particular conditions.
Introduction
Etanercept and infliximab can improve symptoms and function in patient affected by rheumatoid arthritis [1, 2] . Therefore, an increasing numbers of rheumatoid patients are being treated with this kind of drug. On the other hand, tumour necrosis factor-alpha inhibitors (TNF-i) could be associated with a risk for healing and infection complications due to systemic blockade of TNF-alpha able to alter the normal inflammatory response in tissue healing and infection surveillance [2, 3] . Moreover, surgery in rheumatoid patients is becoming more probable in every day practice and could be associated to a higher risk of infections or a lower healing rate in patients treated with these drugs.
We report a case-series where rheumatoid patients underwent various kind of elective surgery but did not withdraw etanercept therapy in spite of physician advise.
Case-series
Five consecutive cases were observed from a large cohort of patients referred to "Civico e Benfratelli" rheumatologic outpatient clinic. All reported cases are all the patients that underwent an elective surgery and did not withdraw etanercept therapy in spite of physician advice. All had undergone etanercept (25 mg twice weekly) from almost 12 months to obtain disease remission before surgery. On 2004, she had also a bladder stone removed by cystoscopy. She had an empirical antibiotic therapy for 10 days.
Case 5
We observed C.G., male, 53 years old, had an RA duration of 13 years, had Steinbrocker stage II, and had a surgically removed left inguinal hernia in 2004. An empirical antibiotic therapy for 12 days was given.
All the patients had a regular healing rate. During follow-ups (6-12 months) no one of these patients were suffering from infection complications after surgery.
Discussion
Rheumatoid patients are at increased risk of infection, and this is of concern after undergoing surgery [4] [5] [6] . On the other hand, surgery procedures in rheumatoid patients are becoming more common, and to stop disease modifying antirheumatic drugs treatment before surgery may result in outbreak of disease activity. Moreover, particularly in orthopedic surgery, the resultant loss of mobility would adversely affect outcome, considering mobilisation is crucial for effective rehabilitation. As expert's opinion, surgery during and after TNF-i treatment appeared to be safe in patients affected by inflammatory bowel disease [7] .
However, surgery-related infection could become a serious complication of concomitant TNF-i therapy. However, very scarce data exist on etanercept therapy in surgical treated rheumatoid patients [8] . The study of Bibbo and Goldberg [9] just analysed the risk of healing/infection complications in patients undergoing elective foot and ankle surgery while being treated with TNF-i etanercept and infliximab. It was a little study of 31 patients, but it was a controlled trial where rheumatoid patients who had undergone TNF-i were compared to those who had not.
All patients underwent elective foot and ankle surgery, and all were prospectively followed for the development of complications in the post-operative period and over a 12-month period.
As following-up of about 10 months, healing or infectious complications were similar in both groups. These data suggest that in patients with rheumatoid arthritis undergoing elective foot and ankle surgery, the use of TNF-i may be safely continued in the perioperative period without increasing the risk of healing or infectious complications.
Notwithstanding these data, controlled clinical trials (better if randomised) are not sufficient to evaluate adverse drug reaction [10] even whether using correct sample size. Post-marketing studies and, better, active adverse drug reaction surveillance need to deeply assess drug safety, in particular, after minor and major surgery. Our observation of a small case-series of surgically treated rheumatoid patients receiving etanercept before, during and after surgery showed no complications due to infection or intolerance, either immediately or later after surgery. These data appear to confirm the tolerability profile of etanercept, in terms of lack of infections or intolerance in such patients. Moreover, we think that every useful data on TNF-i therapy in surgically treated rheumatoid patients could come even from case-series on an international surveillance network basis.
In conclusion, data on drug safety of etanercept in surgically treated rheumatoid patients are scarce and inadequate. We have only tried to share evolving knowledge on this topic. Some evidences suggest safety of concomitant etanercept therapy in surgically treated rheumatoid patients. Accordingly, we believe that is the time to value rheumatoid patient preferences through a correct information about cost-benefit (in terms of adverse drug reactions/post-operative complications versus clinical advantages) of this treatment before and after surgery to establish together with patients if etanercept therapy has to be continued or not. Finally, adverse drug reaction surveillance has to be boosted even with publication of case-series on drug safety and tolerability in particular conditions.
